Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Abstract

Aims: The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). Methods and results: HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (>40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The primary endpoint was 6-minute walk test distance (6MWTD) change to Week 12. Key secondary endpoints included Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) and Chronic Heart Failure Questionnaire Self-Administered Standardized format (CHQ-SAS) dyspnoea score. 6MWTD median (95% confidence interval) differences, empagliflozin vs. placebo, at Week 12 were −4.0 m (−16.0, 6.0; P = 0.42) and 4.0 m (−5.0, 13.0; P = 0.37) in EMPERIAL-Reduced and EMPERIAL-Preserved, respectively. As the primary endpoint was non-significant, all secondary endpoints were considered exploratory. Changes in KCCQ-TSS and CHQ-SAS dyspnoea score were non-significant. Improvements with empagliflozin in exploratory pre-specified analyses of KCCQ-TSS responder rates, congestion score, and diuretic use in EMPERIAL-Reduced are hypothesis generating. Empagliflozin adverse events were consistent with those previously reported. Conclusion: The primary outcome for both trials was neutral. Empagliflozin was well tolerated in HF patients, with and without T2D, with a safety profile consistent with that previously reported in T2D. Hypothesis-generating improvements in exploratory analyses of secondary endpoints with empagliflozin in HFrEF were observed.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehaa943

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Cited by

See all 218

Metadata

Authors
Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., Howlett, J. G., Nicholls, S. J., Redon, J., Schenkenberger, I., Silva-Cardoso, J., Störk, S., Krzysztof Wranicz, J., Savarese, G., Brueckmann, M., Jamal, W., Nordaby, M., Peil, B., Ritter, I., Ustyugova, A., Zeller, C., Salsali, A., & Anker, S. D.
Affiliations
  • The Ohio State University (US)
  • Vanderbilt University Medical Center (US)
  • Wroclaw Medical University (PL)
  • University of Milan (IT)
  • University of Mississippi Medical Center (US)
  • Brigham and Women's Hospital (US)
  • National and Kapodistrian University of Athens (GR)
  • Department of Cardiology, Independent Public Healthcare , General Hospital in Puławy; ul. Bema 1; 24 – 100 Pulawy, Poland
  • Sahlgrenska University Hospital (SE)
  • Oslo University Hospital (NO)
  • University of Calgary (CA)
  • Monash University (AU)
  • INCLIVA Research Institute, University of Valencia , vinguda de Menéndez y Pelayo, 4, 46010 Valencia, and CIBERObn, Madrid, Spain
  • Klinische Forschung Berlin GbR , Ansbacher Str. 17-19, 10787 Berlin, Germany
  • CardioCare, CINTESIS—Center for Health Technology and Services Research, and Director of the Cardiology Service, Porto University Medical School , São João University Medical Centre, Rua Dr. Plácido da Costa, s/n 4200-450, Porto, Portugal
  • University of Würzburg (DE)
  • Department of Electrocardiology, Medical University of Lodz , al. Tadeusza Kościuszki 4, 90-41, Lodz, Poland
  • Karolinska University Hospital (SE)
  • Boehringer Ingelheim (Germany) (DE)
  • Boehringer Ingelheim (United States) (US)
  • Berlin-Brandenburger Centrum für Regenerative Therapien (DE)
Corresponding author
Abraham, William T
Venue
European Heart Journal
Published
2020-12-22
Volume
42
Issue
6
Pages
700-710
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3115628228
Cited by
217
References
28
Citations by year
2026: 21 · 2025: 36 · 2024: 43 · 2023: 47 · 2022: 39 · 2021: 29 · 2020: 2
FWCI
18.10
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
Funders
Boehringer Ingelheim
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Physiology (medical) › Cardiovascular and exercise physiology
Keywords
empagliflozin, heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, type 2 diabetes, SGLT2 inhibitors, exercise capacity, 6-minute walk test, patient-reported outcomes, Kansas City Cardiomyopathy Questionnaire, dyspnea, diuretic use, drug safety and tolerability
MeSH terms
Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Heart Failure, Humans, Stroke Volume

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. https://app.cochat.ai/papers/10.1093/eurheartj/ehaa943
The paper
Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., Howlett, J. G., Nicholls, S. J., Redon, J., Schenkenberger, I., Silva-Cardoso, J., Störk, S., Krzysztof Wranicz, J., Savarese, G., Brueckmann, M., . . . Anker, S. D. (2021). Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal. https://doi.org/10.1093/eurheartj/ehaa943

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.